Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

IP Trougakos, K Stamatelopoulos, E Terpos… - Journal of Biomedical …, 2021 - Springer
Background Gaining further insights into SARS-CoV-2 routes of infection and the underlying
pathobiology of COVID-19 will support the design of rational treatments targeting the life …

Small molecules in the treatment of COVID-19

S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

M Hoffmann, H Hofmann-Winkler, JC Smith… - …, 2021 - thelancet.com
Background Antivirals are needed to combat the COVID-19 pandemic, which is caused by
SARS-CoV-2. The clinically-proven protease inhibitor Camostat mesylate inhibits SARS …

[HTML][HTML] Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

JD Gunst, NB Staerke, MH Pahus, LH Kristensen… - …, 2021 - thelancet.com
Background The trans-membrane protease serine 2 (TMPRSS2) is essential for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy …

RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection

G Liu, W Du, X Sang, Q Tong, Y Wang, G Chen… - Nature …, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to have
devastating consequences worldwide. Recently, great efforts have been made to identify …

An overview on the treatments and prevention against COVID-19

Y Panahi, AM Gorabi, S Talaei, F Beiraghdar… - Virology Journal, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …

Current strategies of antiviral drug discovery for COVID-19

M Mei, X Tan - Frontiers in Molecular Biosciences, 2021 - frontiersin.org
SARS-CoV-2 belongs to the family of enveloped, single-strand RNA viruses known as
Betacoronavirus in Coronaviridae, first reported late 2019 in China. It has since been …

SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models

AZ Mykytyn, TI Breugem, MH Geurts, J Beumer… - Journal of …, 2023 - Am Soc Microbiol
ABSTRACT SARS-CoV-2 can enter cells after its spike protein is cleaved by either type II
transmembrane serine proteases (TTSPs), like TMPRSS2, or cathepsins. It is now widely …

Elucidating the neuropathologic mechanisms of SARS-CoV-2 infection

M Pacheco-Herrero, LO Soto-Rojas… - Frontiers in …, 2021 - frontiersin.org
The current pandemic caused by the new severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has become a public health emergency. To date, March 1, 2021, coronavirus …

A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 …

T Kinoshita, M Shinoda, Y Nishizaki, K Shiraki, Y Hirai… - BMC medicine, 2022 - Springer
Background In vitro drug screening studies have indicated that camostat mesilate (FOY-305)
may prevent SARS-CoV-2 infection into human airway epithelial cells. This study was …